Minerva Neurosciences is a biotechnology business based in the US. Minerva Neurosciences shares (NERV) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $2.24 – an increase of 1.81% over the previous week. Minerva Neurosciences employs 9 staff and has a market cap (total outstanding shares value) of 0.00.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $2.24 |
|---|---|
| 52-week range | $2.07 - $13.49 |
| 50-day moving average | $2.55 |
| 200-day moving average | $3.13 |
| Wall St. target price | $5.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.45 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.24 from 2024-11-22
| 1 week (2024-11-15) | 1.81% |
|---|---|
| 1 month (2024-10-24) | -8.94% |
| 3 months (2024-08-23) | -14.83% |
| 6 months (2024-05-23) | -11.11% |
| 1 year (2023-11-22) | -55.38% |
|---|---|
| 2 years (2022-11-23) | -34.31% |
| 3 years (2021-11-23) | 8.56 |
| 5 years (2019-11-22) | 47.76 |
| Gross profit TTM | $-16,838,947 |
|---|---|
| Return on assets TTM | -28.91% |
| Return on equity TTM | -675.09% |
| Profit margin | 0% |
| Book value | $-3.10 |
| Market Capitalization | $15.5 million |
TTM: trailing 12 months
We're not expecting Minerva Neurosciences to pay a dividend over the next 12 months.
Minerva Neurosciences's shares were split on a 1:8 basis on 20 June 2022 . So if you had owned 8 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Minerva Neurosciences shares – just the quantity. However, indirectly, the new 700% higher share price could have impacted the market appetite for Minerva Neurosciences shares which in turn could have impacted Minerva Neurosciences's share price.
Over the last 12 months, Minerva Neurosciences's shares have ranged in value from as little as $2.0703 up to $13.49. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Minerva Neurosciences's is 0.17. This would suggest that Minerva Neurosciences's shares are less volatile than average (for this exchange).
Minerva Neurosciences, Inc. , a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts. .
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
The best platforms to use for automatic investing include Wealthfront, SoFi, Schwab, Vanguard, Titan, Acorns and more. See our full list here.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
5 Betterment robo-advisor alternatives to consider when building your portfolio.
What you need to know about investing in the leading indicator for the overall US stock market.
How do you gift stocks to loved ones? Learn the ins and outs of finding the right investments for them.
Check out the best-performing ETFs so far in 2024.
Acorns is a financial service that rounds up your purchases and turns the extra change into investments.